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Increasing the Antimicrobial Activity of Nisin-Based
Lantibiotics against Gram-Negative Pathogens
Qian Li,a Manuel Montalban-Lopez,a,b Oscar P. Kuipersa
aDepartment of Molecular Genetics, Groningen Biomolecular Sciences and Biotechnology Institute, University
of Groningen, Groningen, the Netherlands
bDepartment of Microbiology, Faculty of Sciences, University of Granada, Granada, Spain
ABSTRACT Lantibiotics are ribosomally synthesized and posttranslationally mod-
iﬁed antimicrobial compounds containing lanthionine and methyl-lanthionine
residues. Nisin, one of the most extensively studied and used lantibiotics, has
been shown to display very potent activity against Gram-positive bacteria, and
stable resistance is rarely observed. By binding to lipid II and forming pores in
the membrane, nisin can cause the efﬂux of cellular constituents and inhibit cell
wall biosynthesis. However, the activity of nisin against Gram-negative bacteria is
much lower than that against Gram-positive bacteria, mainly because lipid II is
located at the inner membrane, and the rather impermeable outer membrane in
Gram-negative bacteria prevents nisin from reaching lipid II. Thus, if the outer
membrane-traversing efﬁciency of nisin could be increased, the activity against
Gram-negative bacteria could, in principle, be enhanced. In this work, several rel-
atively short peptides with activity against Gram-negative bacteria were selected
from literature data to be fused as tails to the C terminus of either full or trun-
cated nisin species. Among these, we found that one of three tails (tail 2 [T2;
DKYLPRPRPV], T6 [NGVQPKY], and T8 [KIAKVALKAL]) attached to a part of nisin
displayed improved activity against Gram-negative microorganisms. Next, we ra-
tionally designed and reengineered the most promising fusion peptides. Several
mutants whose activity signiﬁcantly outperformed that of nisin against Gram-
negative pathogens were obtained. The activity of the tail 16 mutant 2 (T16m2)
construct against several important Gram-negative pathogens (i.e., Escherichia
coli, Klebsiella pneumoniae, Acinetobacter baumannii, Pseudomonas aeruginosa, En-
terobacter aerogenes) was increased 4- to 12-fold compared to that of nisin. This
study indicates that the rational design of nisin can selectively and signiﬁcantly
improve its outer membrane-permeating capacity as well as its activity against
Gram-negative pathogens.
IMPORTANCE Lantibiotics are antimicrobial peptides that are highly active against
Gram-positive bacteria but that have relatively poor activity against most Gram-
negative bacteria. Here, we modiﬁed the model lantibiotic nisin by fusing parts of it
to antimicrobial peptides with known activity against Gram-negative bacteria. The
appropriate selection of peptidic moieties that could be attached to (parts of) nisin
could lead to a signiﬁcant increase in its inhibitory activity against Gram-negative
bacteria. Using this strategy, hybrids that outperformed nisin by displaying 4- to 12-
fold higher levels of activity against relevant Gram-negative bacterial species were
produced. This study shows the power of modiﬁed peptide engineering to alter tar-
get speciﬁcity in a desired direction.
KEYWORDS nisin, outer membrane, Gram-negative pathogens, antimicrobial
peptide, antimicrobial activity, lantibiotic
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Nisin (Fig. 1), produced by Lactococcus lactis, is the oldest known (since 1928) andmost extensively studied lantibiotic (1, 2). It is a potent lanthionine-containing
antimicrobial peptide that is ribosomally synthesized and posttranslationally modiﬁed.
Unmodiﬁed prenisin contains 57 amino acids, of which the ﬁrst 23 amino acids
correspond to the leader peptide and the last 34 residues compose the core peptide (2).
The leader peptide is crucial for unmodiﬁed prenisin to be recognized by the modiﬁ-
cation and transport proteins (2–4). The precursor is processed by the modiﬁcation
machinery. First, the serine and threonine residues are dehydrated by the NisB dehy-
dratase to become dehydroalanines (Dha) or dehydrobutyrines (Dhb), respectively (2,
3). Dehydrated residues can then be coupled to a cysteine by the cyclization enzyme
NisC (5). Subsequently, the modiﬁed peptide is transported out of the cell by the
transporter NisT (2, 4). At this time, the fully modiﬁed nisin prepeptide is still inactive
because of the presence of the leader peptide. Only after the leader sequence is
cleaved off by the protease NisP does nisin become active and induce the two-
component system NisRK (6, 7). It has been clearly demonstrated that NisB, NisC, and
NisT have a relaxed substrate speciﬁcity, and highly diverse peptides fused to the nisin
leader can be efﬁciently modiﬁed (2, 3, 5, 8, 9).
Nisin has been used in the food industry as a natural preservative for decades,
thanks to its high level of activity against bacteria and low level of toxicity for humans
(2, 10). It is highly effective against Gram-positive bacteria, with its MICs being at
nanomolar concentrations (1, 2, 5). There are two different mechanisms by which nisin
kills bacteria: pore formation in the membrane and inhibition of cell wall biosynthesis
by binding to lipid II (1, 11, 12). After nisin reaches the bacterial plasma membrane, a
pyrophosphate cage which involves the ﬁrst two rings of nisin and the pyrophosphate
moiety of lipid II is formed via hydrogen bonds. The pyrophosphate is responsible for
the low levels of resistance of bacteria to nisin, since the pyrophosphate is essential
and not prone to mutation and also facilitates the transmembrane orientation of
nisin (1, 12).
Nevertheless, it is difﬁcult for nisin to penetrate the outer membrane barrier of
Gram-negative bacteria, and thus, it cannot reach its target, lipid II, in the inner
membrane. This leads to the relatively low level of activity of nisin against Gram-
negative bacteria. Conversely, nisin actually tends to bind to the usually anionic surface
of the outer membrane and stabilizes it via electrostatic interactions (13). Notably, nisin
can inhibit the growth of Gram-negative bacteria more efﬁciently, when chelating
agents (EDTA, citrate monohydrate, or trisodium orthophosphate) are used to desta-
bilize the outer membrane (14, 15). Thus, the main bottleneck for nisin to be active
against Gram-negative bacteria appears to be its ability to pass the outer membrane.
The outer membrane of Gram-negative bacteria constitutes an efﬁcient protective
barrier that prevents various antimicrobials from reaching the cellular membrane and
exerting their function. To address this issue, we have designed hybrid compounds
based on the antimicrobial nisin and other antimicrobial peptides that combine
different functionalities. Thus, we have developed ways to enable antimicrobials to pass
the outer membrane of Gram-negative organisms while retaining as much as possible
their antimicrobial function at the cytoplasmic membrane. Some mutants have been
made previously (16). In those mutants, full nisin or parts of nisin were fused to different
tails with reported activity against Gram-negative bacteria to create antimicrobial
peptides targeted against Gram-negative pathogens (16). These tails are mainly cationic
peptides secreted by amphibians, insects, or immune cells, including proline-rich
antimicrobial peptides (Table 1). Their mechanisms of action are unclear in many cases,
but to reach their targets, it is clear that they must interact with and cross the outer
membrane. Because peptide GNT16 was reported by our group to have 2-fold im-
proved activity against Escherichia coli compared with that of nisin alone (16), in this
work the tail 16 (T16) sequence PRPPHPRL was also used for further engineering. In
addition, we chose several Gram-negative pathogens from the Enterococcus faecium,
Staphylococcus aureus, Klebsiella pneumoniae, Acinetobacter baumannii, Pseudomonas
aeruginosa, and Enterobacter species (ESKAPE) group of pathogens as well as Escherichia
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coli as indicator strains for MIC tests. In the course of the experiments, we did a further
rational design of the peptides on both the tail and the nisin parts. We found that
several hybrid peptides had considerably higher activity than nisin against different
multidrug-resistant (MDR) Gram-negative pathogens. The tail 16 (T16) mutant 2
(T16m2) construct was proven to display the best activity, and it was found to be 4 to
12 times more efﬁcient than nisin, depending on the target organism used. This study
reports on the bioengineering and rational design of nisin and tails with activity against
Gram-negative bacteria to substantially increase the activity of nisin against MDR
Gram-negative pathogens.
RESULTS
Construction of peptide fusions containing a nisin part and a tail with activity
against Gram-negative bacteria. The ﬁrst two rings of nisin can bind to lipid II to
inhibit cell wall synthesis and serve as a docking point for subsequent pore formation
in the membrane (1). However, due to its size, hydrophobicity, and charge, nisin cannot
efﬁciently pass through the outer membrane of Gram-negative bacteria. Fusions con-
taining both the nisin lipid II-binding part (26) and an outer membrane-penetrating
part can kill Gram-negative pathogens more successfully than nisin alone due to the
Trojan horse effect of the added tail (16). Several new compounds were constructed in
which the tail with activity against Gram-negative bacteria was fused to either the A, B,
and C rings (ABC rings) of nisin (data not shown), full nisin (Table 2, group 1), or only
the A, B, C, D, and E rings (ABCDE rings) of nisin (Table 2, group 2). We found that the
FIG 1 Schematic structure of prenisin with a His tag and fusions. Dha, dehydroalanine; Dhb, dehydrobutyrine; Ala-S-Ala, lanthionine; Abu-S-Ala,
-methyllanthionine. Prenisin (gray) contains a leader peptide and a core peptide (1 to 34 amino acids). The 6 histidine residues are located at the N terminus
and labeled in yellow. The ABCDE rings are marked. The structures of fusion peptides are indicated, with the linker being labeled in purple (serine and glycine),
while tails with activity against Gram-negative bacteria are labeled with green. Group 1 contains full nisin and tails with activity against Gram-negative bacteria.
Group 2 contains the ABCDE rings of nisin, the hinge region (serine and glycine), and tails with activity against Gram-negative bacteria.
TABLE 1 Tails fused to a speciﬁc part of nisin
Tail Sequence Reference Source
T1 DKPRPYLPRPRPV 17 Designed antimicrobial peptide based on
statistical analyses
T2 DKYLPRPRPV 17 Designed antimicrobial peptide based on
statistical analyses
T3 PFKISIHL 18 Royal jelly of Apis mellifera
T4 ILPWKWPWWPWRR 19 Cytoplasmic granules of bovine
neutrophils
T5 ILGKILKGIKKLF 20 Opisthacanthus madagascariensis
T6 NGVQPKY 21 White blood cell extracts of Siamese
crocodile
T7 NAGSLLSGWG 21 White blood cell extracts of Siamese
crocodile
T8 KIAKVALKAL 22 Skin secretions of Xenopus laevis
T9 FLPIAGKLLSGLSGLL 23 Skin secretions of Amolops loloensis
T10 FLPGLLAGLL 24 Skin secretions of Euphlyctis cyanophlyctis
T11 AAGMGFFGAR 25 Urechis unicinctus
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expression of fusions including the ABC rings of nisin and the tails was less efﬁcient
than that of the structures in the group 1 and group 2 constructs (data not shown),
which was in agreement with previous reports (16). So, we discuss only the fusions with
full nisin (group 1) or the ﬁve rings of nisin (group 2) in this paper. In order to make the
hybrid peptide shorter and more stable, the amino acid sequence IHVSK was deleted
in the group 2 mutants. In this case, an SG sequence was added to work as a ﬂexible
linker between the ABCDE rings of nisin and the tails (Table 2, group 2). The sequences
of the fusions are listed in Table 2. The structures of these fusions are shown in Fig. 1.
Characterization of fusions by MS and antimicrobial activity. All the fusions
were induced and expressed with the nisin production system in L. lactis and then
precipitated with trichloroacetic acid (TCA). Tricine SDS-PAGE was used to check the
production level of the hybrid peptides. The mass of the peptides before leader peptide
removal was determined via matrix-assisted laser desorption ionization–time of ﬂight
MALDI-TOF mass spectrometry (MS) to assess the modiﬁcation extent of the hybrid
peptides. Simultaneously, the antibiotic activity of the peptides activated using either
in situ-produced (L. lactis) or puriﬁed (E. coli) NisP (27) was tested for qualitative
antimicrobial screening. As Table 3 shows, the production level of some fusions was too
TABLE 2 Fusions including the nisin moiety and tails with activity against Gram-negative bacteria
Tail
Group 1 Group 2
Name Sequence Name Sequence
T1 T1F Nisin  DKPRPYLPRPRPV T1S ABCDE rings  SG  DKPRPYLPRPRPV
T2 T2F Nisin  DKYLPRPRPV T2S ABCDE rings  SG  DKYLPRPRPV
T3 T3F Nisin  PFKISIHL T3S ABCDE rings  SG  PFKISIHL
T4 T4F Nisin  ILPWKWPWWPWRR T4S ABCDE rings  SG  ILPWKWPWWPWRR
T5 T5F Nisin  ILGKILKGIKKLF T5S ABCDE rings  SG  ILGKILKGIKKLF
T6 T6F Nisin  NGVQPKY T6S ABCDE rings  SG  NGVQPKY
T7 T7F Nisin  NAGSLLSGWG T7S ABCDE rings  SG  NAGSLLSGWG
T8 T8F Nisin  KIAKVALKAL T8S ABCDE rings  SG  KIAKVALKAL
T9 T9F Nisin  FLPIAGKLLSGLSGLL T9S ABCDE rings  SG  FLPIAGKLLSGLSGLL
T10 T10F Nisin  FLPGLLAGLL T10S ABCDE rings  SG  FLPGLLAGLL
T11 T11F Nisin  AAGMGFFGAR T11S ABCDE rings  SG  AAGMGFFGAR




Predicted mass (Da) (no. of
dehydrations measured/




N terminus C terminus
T1 T1F  8,195.66 (9/9) \ \ \
T1S  7,706.02 (8/8) \ \ \
T2 T2F  5,506.52 (9/9) 5,507.13 ΔMHHHHHHSTKDFNLDL ΔRPV
T2S  4,897.79 (8/8) 4,898.44 ΔMHHHHHHSTKDFNLDLVSVS ΔV
T3 T3F  7,540.94 (10/10) \ \ \
T3S  7,051.31 (9/9) \ \ \
T4 T4F  8,512.07 (9/9) \ \ \
T4S  8,022.43 (8/8) \ \ \
T5 T5F  8,075.71 (9/9) \ \ \
T5S  7,586.08 (8/8) \ \ \
T6 T6F  7,460.61 (6/9) 7,461.76 No No
T6S  6,953.30 (6/8) 6,952.85 No No
T7 T7F  7,580.67 (8/11) 7,582.97 No No
T7S  7,127.35 (5/10) 7,129.11 No No
T8 T8F  6,943.14 (9/9) 6,945.21 ΔMHH ΔKAL
T8S  5,740.77 (6/8) 5,740.07 ΔMHHHHHHS ΔLKAL
T9 T9F  8,167.76 (11/11) \ \ \
T9S  7,678.12 (10/10) \ \ \
T10 T10F  7,021.13 (9/9) 7,023.29 ΔM ΔLAGLL
T10S  6,167.19 (8/8) 6,165.97 ΔMHHHH ΔGLL
T11 T11F  7,603.90 (8/9) 7,601.46 No No
T11S  7,135.27 (6/8) 7,139.26 No No
a, visible on tricine SDS-polyacrylamide gel; , not visible on tricine SDS-polyacrylamide gel; \, no detectable peak in MALDI-TOF MS.
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low to show a clearly visible band in tricine SDS-PAGE, while some others were
produced with high yields comparable to the yield of wild-type nisin produced using
the same system (see Fig. S1 in the supplemental material). The mass results indicate
that the peptides T6F/S, T7F/S, and T11F/S were not fully dehydrated. In all cases, a
minimum of 5 dehydrations was detected. Considering the N-to-C directionality of
NisBC, 5 dehydrations are enough to correctly construct ABC rings which preserve the
lipid II-binding capacity of nisin and retain partial antimicrobial activity (26, 28). We
observed that the mutant peptides T2F/S, T10F/S, and T8F/S rendered a peptide with
a mass smaller than the predicted mass. This might be due to degradation during
production or TCA precipitation. The nonspeciﬁc cleavage site in these peptides was
not dependent on the sequence of the tail since the mass difference between fusions
to full nisin and fusions to the ABCDE rings was not conserved (i.e., the full nisin and
group 2 fusions were truncated differently). This phenomenon has been previously
observed with fusions between nisin and tails with activity against Gram-negative
bacteria (16). All of them exerted relatively high activity against L. lactis
NZ9000(pNZnisP8H), but only T2F, T6F, T8F, and T8S showed activity against E. coli
CECT101 (Fig. 2). This was probably observed because the ﬁrst two rings of nisin can
bind to lipid II, while the last two rings can participate in pore formation, leading to the
death of L. lactis (26, 27). It could also be partly due to the sensitivity of L. lactis
NZ9000(pNZnisP8H), which was selected in the ﬁrst screening for its reported increased
sensitivity (27). Thus, even poorly active or poorly produced compounds with activity
FIG 2 Screening the hybrid peptides against L. lactis and E. coli CECT101. Thirty microliters of TCA-precipitated supernatants produced by L. lactis
NZ9000(pIL3EryBTC/pNZ-mutant) was deposited on the wells. T1F to T11F, group 1 hybrid peptides containing full nisin fused to tails with activity against
Gram-negative bacteria; T1S to T11S, group 2 hybrid peptides containing ABCDE rings of nisin and the hinge region (serine and glycine) fused to tails with
activity against Gram-negative bacteria; nisA, the positive control, consisting of a TCA-precipitated supernatant of NZ900(pIL3EryBTC/pNZ-nisA); empty,
negative control, consisting of the precipitated supernatant of NZ9000(pIL3EryBTC/pNZ8048). The indicator strains were L. lactis NZ9000(pNZnisP8H) (A to C)
and E. coli CECT101 (D to F).
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against L. lactis NZ9000(pNZnisP8H) that would otherwise have been discarded during
a screening against solely E. coli could be detected.
Designing mutants of tail 6, tail 8, and GNT16. Fusions containing tails 2, 6, and
8 showed a good potential for further tests for their activity against Gram-negative
pathogens. In addition, GNT16 has been reported by our group before to have
relatively good trans-outer membrane activity (16). Both tail 2 (DKYLPRPRPV) and tail 16
(PRPPHPRL) are proline-rich peptides, like GNT16. So, tails 6, 8, and 16 were selected to
be rationally modiﬁed and further studied, as shown in Table 4. For TXm1 (where X is
tail 6, 8, or 16), a hydrophilic and positively charged lysine was added at the C terminus
of the peptides TXS (where X is tail 6, 8, or 16), because many lantibiotics have a lysine
at the C terminus. In the mutants TXm2 (where X is tail 6, 8, or 16), the glycine in the
linker region between the nisin moiety and the tail in TXm1 was replaced by valine,
since valine can make this region a bit less ﬂexible. TXm3 (where X is tail 6, 8, or 16)
mutants were composed of ﬁve rings of nisin and tails with SV between. TXm4 (where
X is tail 6, 8, or 16) mutants were designed in a totally different manner, using the
peptide tail sequences with activity against Gram-negative bacteria as the hinge region
between the ABC rings and DE rings of nisin, thus replacing the original NMK in the
hinge region (Table 4).
Characterization of puriﬁed leaderless peptides. The active peptides were ac-
quired by puriﬁcation and digestion using puriﬁed NisP (27) to remove the leader part
and activate the peptide. Their masses were measured by MALDI-TOF MS (Fig. S2), and
the mass results are listed in Table 5, which also shows the yields of the peptides. The
results show that the peptides with tails 6 and 16 were not fully dehydrated, while
peptides containing tail 8 were most likely degraded during the process of production
or puriﬁcation by exoproteases. T8m4, where the tail was placed as a hinge region and
therefore not accessible to exoproteases, stayed as a full-length peptide, and no
degradation was observed. The alkylation reaction with 1-cyano-4-dimethylamino-
pyridinium tetraﬂuoroborate (CDAP) proved that there were no free thiol groups in the
peptides (Fig. S3). This fact, together with the activity, strongly suggests that the
lanthionine rings possess the right regiochemistry.
Activity of the constructed fusions against Gram-negative pathogens. Tests of
the activity of the fusion mutants of T6, T8, and T16 against ﬁve Gram-negative
pathogens were performed. The results of the MIC tests are provided in Table 6. It is
clear that the potency of nisin against these Gram-negative pathogens is reduced in
comparison to the activity at nanomolar concentrations that it displays against L. lactis.
The MIC value of the designed peptides ranged from 6 M, needed to inhibit A.
baumannii, to more than 48 M, needed to inhibit K. pneumoniae. The activity of most
of the mutants slightly outperformed that of nisin against some of the strains tested. A
noteworthy ﬁnding was that T6F had improved activity over that of nisin against ﬁve
out of the six strains tested, including K. pneumoniae.
After further design, TXm2 (where X is tail 6, 8, or 16) had lower MIC values than
TXm1, TXm3, TXm4, and, especially, T16m2. T16m2 displayed 4 to 12 times better
TABLE 4Mutants for T6, T8, and GNT16
Name Sequence
T6m1 ABCDE rings  SG  NGVQPKYK
T6m2 ABCDE rings  SV  NGVQPKYK
T6m3 ABCDE rings  SV  NGVQPKY
T6m4 ABC rings  NGVQPKY  DE rings  SIHVSK
T8m1 ABCDE rings  SG  KIAKVALKALK
T8m2 ABCDE rings  SV  KIAKVALKALK
T8m3 ABCDE rings  SV  KIAKVALKAL
T8m4 ABC rings  KIAKVALKAL  DE rings  SIHVSK
T16m1 ABCDE rings  SG  PRPPHPRLK
T16m2 ABCDE rings  SV  PRPPHPRLK
T16m3 ABCDE rings  SV  PRPPHPRL
T16m4 ABC rings  PRPPHPRL  DE rings  SIHVSK
Li et al. Applied and Environmental Microbiology
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activity than nisin against all the Gram-negative pathogens used, including Enterobacter
aerogenes and K. pneumoniae, which were the bacteria most resistant to these com-
pounds under the conditions tested. Of note, T16m2 was 12 times more active than
nisin against K. pneumoniae (a -lactamase-producing strain) and A. baumannii.
On the other hand, among the mutants, TXm4 (where X is tail 6, 8, or 16) showed
the worst activity against Gram-negative pathogens. None of these peptides displayed
improved activity but, rather, displayed a drastic increase in the MIC value.
TABLE 6MICs of nisin, fusion peptides, and tailsa
aMICs are in micromolars. Green, nisin and MIC values of nisin; red, MIC values which were lower than
those of nisin; ND, not determined. The data in the last three rows represent the activity of the synthetic
added tails alone, the sequences of which were as follows: NGVQPKYK for Tail T6m2, KIAKVALKALK for Tail
T8m2, and PRPPHPRLK for Tail T16m2.
TABLE 5MS analysis and yields of leaderless peptides used for activity testa
Name
Predicted mass (Da) (no. of
dehydrations measured/







T6F 4,160.07 (7/9) 4,158.66 No 834
T6S 3,652.44 (7/8) 3,654.34 No 940
T6m1 3,780.61 (7/8) 3,778.06 No 1,218
T6m2 3,822.69 (7/8) 3,822.82 No 1,138
T6m3 3,676.52 (8/8) 3,678.67 No 740
T6m4 3,768.60 (8/9) 3,766.75 No 1,460
T8F 4,186.14 (9/9) 4,186.03 ΔAL 740
T8S 3,324.08 (6/8) 3,322.60 ΔVALKAL 640
T8m1 3,696.83 (8/8) 3,695.53 ΔALK 246
T8m2 3,777.70 (6/8) 3,777.98 ΔALK 299
T8m3 3,366.16 (6/8) 3,366.81 ΔVALKAL 260
T8m4 4,035.99 (7/9) 4,033.09 No 414
GNT16 4,324.32 (7/9) 4,326.29 No 340
GNT16SG 3,816.69 (7/8) 3,815.64 No 264
T16m1 3,944.87 (7/8) 3,941.44 No 234
T16m2 3,966.00 (8/8) 3,966.68 No 498
T16m3 3,855.90 (7/8) 3,854.75 No 316
T16m4 3,932.85 (8/9) 3,930.71 No 483
Nisin 3,352.61 (8/9) 3,354.75 No NDb
aNisin was puriﬁed from a commercial 2.5% preparation.
bND, not determined.
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Unraveling the effect of the fusions on nisin activity. The added tails for the best
three candidates, T6m2, T8m2 and T16m2, were synthesized as small peptides and
tested for their activity against Gram-negative pathogens and the Gram-positive bac-
terium L. lactis MG1363. The MIC values are listed in Table 6. None of the three tails
alone showed activity against Gram-negative pathogens at the concentrations tested,
with the MIC values being higher than 256 M. Similarly, none of these three tail
peptides could inhibit the growth of L. lactis at a concentration of 32 M. These results
indicate that the main role of the added tails was to assist the nisin part to pass through
the outer membrane, thus working as a carrier or gate opener.
Next we investigated the effect of the added tails on the intrinsic killing mechanism
of nisin. We used the Gram-positive bacterial species L. lactis as a model organism and
confronted it with TXm2 and TXm4 mutants, where the tail behaves either as a
C-terminal addition or as a hinge region, respectively. The MIC values of nisin and 6
fusions, i.e., T6m2, T8m2, T16m2, T6m4, T8m4, and T16m4, are listed in Table 6. The MIC
values of these 6 peptides were 62 times, 50 times, 42 times, 42 times, 33 times, and
83 times higher than the MIC of nisin, respectively. This clearly indicates that the tails
have a negative inﬂuence on the intrinsic activity of nisin on the cytoplasmic mem-
brane.
Effect of EDTA on the activity of nisin against Gram-negative pathogens. As
reported before (13), when sufﬁcient EDTA is added, a smaller amount of nisin is
needed to kill Gram-negative bacteria. In order to assess if the fusions changed the
spectrum of activity of nisin, we decided to compare the MIC of nisin in the presence
of EDTA with that of the fusion peptides alone. In this work, different concentrations of
EDTA were added together with nisin to test their activity against Gram-negative
pathogens. Untreated cells were used as a positive control. The results are listed in
Table 7. We could see that the pathogens displayed a different sensitivity to nisin when
EDTA was used as an adjuvant. When 50 M EDTA was added, the MIC value of nisin
against E. coli and P. aeruginosa decreased 2 times, while the MIC value against K.
pneumoniae, A. baumannii and E. aerogenes did not change. At least 100 M EDTA was
needed to reduce the MIC value more than 2-fold, with the MIC for K. pneumoniae
being an exception. When comparing these MIC data (Table 7) and those for the nisin
fusions alone (Table 6), it was very obvious that the spectrum of activity of nisin was
changed in the presence of either EDTA or the added tails.
Bactericidal effect of T16m2. The bactericidal effect of T16m2, the best candidate
in our hands, was determined. Unlike the positive controls (untreated cells), no colonies
of E. coli or A. baumannii could grow after incubation with T16m2 (10-fold MIC)
overnight (Fig. 3). There was no growth recovery after exposure to T16m2, so T16m2
was proven to be bactericidal.
DISCUSSION
Antimicrobial resistance has become an imminent and ever-increasing global prob-
lem which threatens public health and economic development. It has been reported
that hospital infections caused by P. aeruginosa and A. baumannii are difﬁcult to treat,
since these pathogens are often resistant to most of the drugs used clinically (29). What
is more, E. aerogenes and K. pneumoniae strains resistant to carbapenem and cepha-
TABLE 7MIC of nisin against Gram-negative pathogens in the presence of EDTA
Concn of
EDTA (M)











0 12 48 36 6 32
50 6 48 18 6 32
100 3 36 9 3 8
200 3 24 2.25 1.5 8
400 1.5 12 0.6 0.75 4
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losporins have already been isolated (29, 30). There are pressing and urgent demands
for the discovery of new antimicrobials to act against Gram-negative pathogens.
Various authors indicate that antimicrobial peptides can constitute a suitable source of
novel compounds with activity against Gram-negative bacteria. In this work, we inves-
tigated rationally designed nisin mutants for this purpose.
Nisin is the best-studied lantibiotic and exhibits high activity against Gram-positive
bacteria, while its activity against Gram-negative microorganisms is drastically reduced.
The outer membrane of Gram-negative bacteria acts as a good protective barrier for
nisin to pass through and thereby prevents nisin from reaching the inner membrane.
In the presence of chelating agents or sublethal outer membrane perturbation, nisin
can inhibit the growth of Gram-negative bacteria. However, the chelators or stress is
not appropriate for most applications. In order to increase the ability of nisin to reach
the inner membrane, we performed extensive engineering in this work. We chose a set
of peptides that can naturally target Gram-negative bacteria and designed nisin fusions
with tails that work as a Trojan horse. Their activities against ﬁve clinically relevant
(drug-resistant) Gram-negative bacterial species were assayed. We created functional
fusions between nisin, which combines with the pyrophosphate in lipid II (an under-
exploited drug target), and several peptides with the capacity to cross the outer
membrane of Gram-negative bacteria.
The peptides with activity against Gram-negative bacteria were selected primarily
on the basis of their capability of outer membrane penetration and their inclusion in
different structural groups (proline-rich, arginine-rich, or cationic peptides). The pre-
liminary screening and previous data focused our interest on tails 6, 8, and 16 fused to
FIG 3 Determination of viable cells after treatment with fusion peptides. (A) Positive control for E. coli, consisting of 50 l of a 100-fold-diluted sample from
the well with E. coli alone; (B) 50 l of a diluted sample from the well in which E. coli was treated with T16m2; (C) medium control (no bacteria were inoculated
in this well); (D) positive control for A. baumannii, consisting of 50 l of a 100-fold-diluted sample from the well with A. baumannii alone; (E) 50 l of a
100-fold-diluted sample from the well in which A. baumannii was treated with T16m2; (F) medium control (no bacteria were inoculated in this well).
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the ABCDE rings of nisin. We conﬁrmed that adding a tail with activity against
Gram-negative bacteria to either nisin or a truncated version of nisin is an efﬁcient way
to improve the activity of nisin against Gram-negative pathogens. However, the addi-
tion of an extra stretch of amino acids can make it prone to partial proteolytic
degradation, as we could observe for the T2, T8, and T10 mutants (Table 3). These
mutants rendered one major product that had a reduced mass but that still retained
activity.
The set of mutants where the tail with activity against Gram-negative bacteria
replaced nisin’s hinge region, TXm4 (where X is tail 6, 8, or 16), failed to show activity
against Gram-negative pathogens in this study. However, they still retained activity
against L. lactis MG1363 (Table 6). Thus, the outer membrane-penetrating capacity of
the TXm4 mutants was, in the best case, minimal, which indicates that the tails used in
our study could optimally perform the expected activity when they were used as
C-terminal extensions of nisin. Moreover, the results conﬁrmed that changes in the
hinge region affect the structure and activity of the entire peptide (31). The location of
the tail in the hinge region in TXm4 decreased its outer membrane-traversing capacity
and, therefore, that of the whole fusion peptide. Our results clearly discourage the use
of the selected tails as a replacement of the nisin hinge region for antimicrobial activity
improvement.
Variations in the region linking ring E of nisin to the peptide with activity against
Gram-negative bacteria (the Gly-to-Val mutation in T8m3 and T16m3) exerted better
activity against speciﬁc pathogens than T8S and GNT16SG, respectively. T8m3 was 2
times more active than T8S against K. pneumoniae, while T16m3 was more than 4 times
more active than GNT16SG. T16m3 was remarkably more active than GNT16SG against
E. coli (MICs, 8 M and 32 M, respectively), K. pneumoniae (MICs, 16 M and 64
M, respectively), A. baumannii (MICs, 1 M and 8 M, respectively), and E. aerogenes
(MICs, 16 M and 32 M, respectively). These results establish that replacing glycine
with valine in the linker region signiﬁcantly enhances the activity of these peptides
against the tested Gram-negative pathogens.
Since most lantibiotics described previously in the literature either contain a posi-
tively charged amino acid at the C terminus or have undergone speciﬁc enzymatic
C-terminal decarboxylation, a set of mutants with an extra lysine was created to mimic
that situation. T8m2 was 2 to 6 times more active than nisin against selected patho-
genic strains. The activity of T16m2 against P. aeruginosa, E. coli, and E. aerogenes was
enhanced 4.5 times, 6 times, and 8 times, respectively. Most notably, the MIC value of
T16m2 against K. pneumoniae and A. baumannii was 12 times lower than that of nisin.
T16m1, T16m2, and T16m3 shared the same tail with activity against Gram-negative
bacteria with GNT16 and GNT16SG, but T16m2 rendered the best results, followed by
T8m2. The difference in the MIC value of T16m2 from that of GNT16SG against E. coli
and K. pneumoniae was more than 16-fold. This ﬁnding indicates the importance of a
C-terminal lysine as well as valine in the ﬂexible linker region connecting nisin and the
tail. The reason might be that the lysine residue at the C terminus has a better
interaction with the negatively charged phospholipids to facilitate translocation, while
a valine in the linker region might facilitate interaction with the membrane lipophilic
part. However, the effect of the Gly-to-Val mutation was detrimental for the activity of
T16m3. This effect was counteracted when lysine was added in T16m2, which outper-
formed mutant T16m1, where glycine is present. Collectively, our results show that the
simultaneous mutation of glycine to valine and the insertion of a C-terminal lysine
improved the antimicrobial activity of all the constructs.
T6m2, T8m2, and T16m2 were proven to be the best candidates in their speciﬁc
similar tail sets. As shown in Table 6, the low levels of activity of the tails of T6m2, T8m2,
and T16m2 alone against Gram-negative pathogens (MIC value  256 M) and the
Gram-positive bacterium L. lactisMG1363 (MIC value 32 M) illustrates the role of the
tails as mainly transmembrane carriers rather than as bactericidal agents themselves.
The nisin-tail fusions were more than 50 times less potent against L. lactis MG1363 than
nisin. Thus, the activity of the nisin part on the inner membrane was extremely
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compromised by addition of the tails. After treatment with different concentrations of
EDTA, a smaller amount of nisin was needed to kill the Gram-negative pathogens.
However, the spectrum of activity of the nisin fusions against Gram-negative pathogens
was different from that of nisin against Gram-negative pathogens that had been
treated with EDTA. T16m2 was shown to be 6 times, 12 times, 4.5 times, 12 times, and
8 times more active than nisin against E. coli, K. pneumoniae, P. aeruginosa, A. bauman-
nii, and E. aerogenes, respectively. For comparison, these pathogens treated with 200
M EDTA were 4 times, 2 times, 16 times, 4 times, and 4 times more sensitive to nisin,
respectively (Table 7). We also showed that T16m2 exerts a bactericidal effect against
E. coli and A. baumannii (Fig. 3). In conclusion, the tails of the fusions changed both the
activity and the spectrum of activity of nisin, but the fusion was still bactericidal.
Previous work (16) showed that the activity of the model lantibiotic nisin against E.
coli can be improved 2-fold by combination of the functional domains of different
antimicrobial peptides, namely, apidaecin and nisin. Our data show that by rational
design it is possible to further improve the activity of nisin up to 12-fold against
selected pathogenic (drug-resistant) Gram-negative bacteria either in healthcare or in
food. These data provide new design principles for further engineering that can lead to
the development of highly potent lantibiotic derivatives speciﬁcally targeting Gram-
negative bacteria. Applications could range from food protection to clinical applica-
tions. For the latter, further preclinical studies on toxicity, stability, hemolysis, and
pharmacokinetics/pharmacodynamics would be required.
MATERIALS AND METHODS
Bacterial strains and growth conditions. The bacteria used in this study are listed in Table 8. L. lactis
strains were cultured in M17 broth supplemented with 0.5% (wt/vol) glucose (GM17) or GM17 agar for
genetic manipulation or in minimal expression medium (MEM) (3) for protein expression at 30°C.
Escherichia coli, Klebsiella pneumoniae, Pseudomonas aeruginosa, Acinetobacter baumannii, and En-
terobacter aerogenes were grown in shaken Luria-Bertani (LB) broth or on LB agar at 37°C. The bacterial
strains with the preﬁx LMG were obtained from the Belgian Coordinated Collections of Microorganisms
(BCCM).
Chloramphenicol and/or erythromycin was used at 5 g/ml when necessary.
Molecular cloning. Molecular cloning techniques were performed as described by Sambrook and
Russell (35). Preparation of competent cells and transformation were performed as described by Holo and
Nes (36). Restriction enzymes and ligase were supplied by Thermo Fisher.
Construction of expression vectors. The peptidic tails were added to nisin genetically by round
PCR. The primers (Table 9) were designed to insert the tails between the nisin part and the restriction site
HindIII. Each pair of primers contained a part annealing with the template vector pNZnisA leader His2 and
a part encoding the peptide tail.
After ampliﬁcation, the PCR cleanup products were digested using DpnI to digest the template and
ligated overnight. The ligation product was desalted and transformed into strain NZ9000, isolated,
extracted, and sequenced to verify the integrity of the sequence.
Protein expression. Each vector containing the mutant structural gene was transformed into
NZ9000(pIL3EryBTC). Cells were ﬁrst cultured overnight in GM17 medium with 5 g/ml chloramphenicol
and 5 g/ml erythromycin and transferred into MEM (3) at a ﬁnal concentration of 2%. Nisin (5 ng/ml)
was added at the beginning of the inoculation and when the culture reached an optical density at 600
nm (OD600) of 0.4 to 0.6. Cells were harvested 3 h after the second induction by centrifugation for 20 min
at 6,500 rpm at 4°C. The supernatant was kept for puriﬁcation.
Protein puriﬁcation, characterization, and quantiﬁcation. For fast detection of the designed
peptides, a small volume of culture supernatant was used for precipitation using trichloroacetic acid
(TCA) as described by Sambrook and Russell (35), and the concentrated peptides were loaded on a 16%
tricine SDS-polyacrylamide gel (37). Alternatively, for larger-volume (1-liter) cultures, the peptide was
concentrated by cationic exchange chromatography and gel ﬁltration (28). Samples were freeze-dried
afterwards.
The freeze-dried sample was dissolved in 50 mM ammonium acetate, pH 6.0, for overnight digestion
with puriﬁed NisP (27). The active peptide was further puriﬁed by high-performance liquid chromatog-
raphy (HPLC) as indicated elsewhere (31). The fractions were collected, tested for activity against L. lactis,
and analyzed by MALDI-TOF MS (34). The active and pure fraction was lyophilized and stored as a powder
until further use.
The quantiﬁcation was performed by HPLC, as described previously (34). The synthetic peptides
T6m2, T8m2, and T16m2 were synthesized and provided with 99% purity by Proteogenix (France).
Nisin was puriﬁed from commercial 2.5% powder as described by Slootweg et al. (38).
Free-thiol alkylation. To investigate whether the fusions possessed free cysteine residues, reactions
with 1-cyano-4-dimethylaminopyridinium tetraﬂuoroborate (CDAP) were performed. A linear peptide,
ADP (H-GIGKHVGKALKGLKGLLKGLGEC-OH), was used as a control. The reaction with CDAP was per-
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formed as described previously (39). The mass spectra before and after the reaction were recorded via
MALDI-TOF MS (34).
Determination of antimicrobial activity and MIC. Antimicrobial activity was performed by a well
diffusion assay as described previously (34). MIC tests were performed in triplicate by liquid growth
inhibition microdilution assays according to standard methods at 37°C overnight (40). Growth inhibition
was assessed by measuring the OD600 using a microplate reader (Tecan Inﬁnite F200). The lowest
concentration of the antimicrobials that inhibited detectable growth of the indicator strain was identiﬁed
as the MIC.
TABLE 8 Strains and plasmids used in this worka
Strain or plasmid Characteristic Purpose Reference or source
Strains
Lactococcus lactis NZ9000 nisRK Expression host and indicator strain 32
Lactococcus lactis NZ9000(pNZnisP8H) nisP Indicator strain 27
Lactococcus lactis MG1363 Indicator strain 33
Escherichia coli CECT101 Indicator strain Lab collection
Escherichia coli LMG15862 -Lactamase Indicator strain Lab collection (BCCM)
Klebsiella pneumoniae LMG20218 -Lactamase Indicator strain Lab collection (BCCM)
Pseudomonas aeruginosa LMG6395 Indicator strain Lab collection (BCCM)
Acinetobacter baumannii LMG01041 Indicator strain Lab collection (BCCM)
Enterobacter aerogenes LMG02094 Indicator strain Lab collection (BCCM)
Plasmids
pNZnisA leader his2 Cmr nisA, encoding nisin, with 6 His
residues inserted behind the ﬁrst
methionine
Expression vector, expression with
a 6-His-tagged nisin
16
pNZ8048 Cmr Expression vector, used as the
negative control in activity test
7
pIL3EryBTC Eryr nisBTC, under the control of
PnisA
Modiﬁcation and transport of
lantibiotics
34
pNZnisA T6 Cmr nisA, T6 Expression of nisin with a 6-His tag
and a NGVQPKY tail
This work
pNZnisA T6S Cmr nisA(Δ30–34), GNGVQPKY Expression of hybrid peptide with a
6-His tag
This work
pNZnisA T8 Cmr nisA, T8 Expression of nisin with a 6-His tag
and a KIAKVALKAL tail
This work
pNZnisA T8S Cmr nisA(Δ30–34), GKIAKVALKAL Expression of a hybrid peptide with
a His tag
This work
pNZnisA GNT16 Cmr nisA, GNT16 Expression of nisin with a 6-His tag
and a PRPPHPRL tail
16
pNZnisA GNT16S Cmr nisA(Δ30–34), GPRPPHPRL Expression of a hybrid peptide with
a 6-His tag
16
pNZnisA Ts Cmr nisA, Ts Expression of nisin or nisin(Δ30–34)
with a 6-His tag and the tails
listed in Table 2
This work
pNZnisA T6m1 to pNZnisA T6m3 Cmr nisA, T6 mutants Expression of a hybrid peptide
containing nisin(Δ30–34) with a
6-His tag and the tails listed in
Table 4
This work
pNZnisA T6m4 Cmr, T6 as the hinge region
between the ABC rings and the
DE rings of nisin
Expression of a hybrid peptide This work
pNZnisA T8 m1 to pNZnisA T8 m3 Cmr nisA, T8 mutants Expression of a hybrid peptide
containing nisin(Δ30–34) with a
6-His tag and the tails listed in
Table 4
This work
pNZnisA T8m4 Cmr, T8 as the hinge region
between the ABC rings and the
DE rings of nisin
Expression of a hybrid peptide This work
pNZnisA T16 m1 to pNZnisA T16 m13 Cmr nisA, T16 mutants Expression of a hybrid peptide
containing nisin(Δ30–34) with a
6-His tag and the tails listed in
Table 4
This work
pNZnisA T16m4 Cmr, T16 as the hinge region
between the ABC rings and the
DE rings of nisin
Expression of a hybrid peptide This work
aCmr, chloramphenicol resistance; Eryr, erythromycin resistance; nisA(Δ30–34), deletion of gene coding IHVSK in nisA; and nisin(Δ30–34), deletion of IHVSK in nisin.
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Bactericidal activity assay. Gram-negative bacteria were incubated in 96-well microplates at 37°C
overnight in the presence of nisin mutants at a ﬁnal concentration of 10 times the MIC. The number of
bacterial cells was standardized to a ﬁnal concentration of 5  105 CFU/ml. Assays with two controls in
fresh LB broth with or without the bacterial inoculum were also performed in parallel under the same
conditions. An aliquot was taken from each well and serially diluted in sterile phosphate-buffered saline.
Afterwards, 50 l of each dilution was plated on LB agar plates. After overnight incubation at 37°C, the
bacterial colonies were enumerated to determine the amount of viable cells.
TABLE 9 Primers for PCRs used in this study
Mutant Primer Nucleotide sequence
T1F T1 Fwd TCC ATA CCT TCC ACG TCC ACG TCC AGT TTA AGC TTT CTT TGA ACC AAA ATT AG
T1F Rev GTG GAA GGT ATG GAC GTG GTT TAT C TT TGC TTA CGT GAA TAC TAC AAT G
T1S T1S Rev GTG GAA GGT ATG GAC GTG GTT TAT CAC CAC TAC AAT GAC AAG TTG CTG
T2F T2 Fwd AAA TAC CTT CCA CGT CCA CGT CCA GTT TAA GCT TTC TTT GAA CCA AAA TTA G
T2F Rev CGT GGA CGT GGA AGG TAT TTA TC T TTG CTT ACG TGA ATA CTA CAA TG
T2S T2S Rev TGG ACG TGG AAG GTA TTT ATC ACC ACT ACA ATG ACA AGT TGC T
T3F T3 Fwd AAA ATC TCA ATC CAC CTT TAA GCT TTC TTT GAA CCA AAA TTA G
T3F Rev TAA AGG TGG ATT GAG ATT TTG AAT GGT TTG CTT ACG TGA ATA CTA C
T3S T3S Rev GGT GGA TTG AGA TTT TGA ATG GAC CAC TAC AAT GAC AAG TTG
T4F T4 Fwd GCC ATG GTG GCC ATG GCG TCG TTA AGC TTT CTT TGA ACC AAA ATT AG
T4F Rev GGC CAC CAT GGC CAT TTC CAT GGA AGG AT T TTG CTT ACG TGA ATA CTA CAA T
T4S T4S Rev GGC CAC CAT GGC CAT TTC CAT GGA AGG ATA CCA CTA CAA TGA CAA GTT G
T5F T5 Fwd AAG GTA TCA AAA AAC TTT TCT AAG CTT TCT TTG AAC CAA AAT TAG
T5F Rev TTG ATA CCT TTA AGG ATT TTA CCA AGG ATT TTG CTT ACG TGA ATA CTA C
T5S T5S Rev TTG ATA CCT TTA AGG ATT TTA CCA AGG ATA CCA CTA CAA TGA CAA GTT G
T6F T6 Fwd GGT GTT CAA CCA AAA TAC TAA GCT TTC TTT GAA CC
T6F Rev ATT TTG GTT GAA CAC CGT TTT TGC TTA CGT GAA TAC TAC
T6S T6S Rev ATT TTG GTT GAA CAC CGT TAC CAC TAC AAT GAC AAG TTG
T7F T7 Fwd TCA CTT CTT TCA GGT TGG GGT TAA GCT TTC TTT GAA CCA AAA TTA G
T7F Rev CCA ACC TGA AAG AAG TGA ACC AGC GTT TTT GCT TAC GTG AAT ACT AC
T7S T7S Rev AAC CTG AAA GAA GTG AAC CAG CGT TAC CAC TAC AAT GAC AAG TTG C
T8F T8 Fwd AAG TTG CTC TTA AAG CTC TTT AAG CTT TCT TTG AAC CAA
T8F Rev CTT TAA GAG CAA CTT TAG CGA TTT TTT TGC TTA CGT GAA TAC TAC AAT G
T8S T8S Rev CTT TAA GAG CAA CTT TAG CGA TTT TAC CAC TAC AAT GAC AAG TTG
T9F T9 Fwd ACT TCT TTC AGG TCT TTC AGG TCT TCT TTA AGC TTT CTT TGA ACC AAA ATT AG
T9F Rev GAA AGA CCT GAA AGA AGT TTA CCA GCG ATT GGA AGG AAT TTG CTT ACG TGA ATA CTA C
T9S T9S Rev GAA AGA CCT GAA AGA AGT TTA CCA GCG ATT GGA AGG AAA CCA CTA CAA TGA CAA GTT G
T10F T10 Fwd CAG GTC TTC TTG CTG GTC TTC TTT AAG CTT TCT TTG AAC CAA AAT TAG
T10F Rev CAG CAA GAA GAC CTG GAA GGA ATT TGC TTA CGT GAA TAC TAC AAT G
T10S T10S Rev CAG CAA GAA GAC CTG GAA GGA AAC CAC TAC AAT GAC AAG TTG
T11F T11 Fwd TGG GTT TCT TCG GTG CTC GTT AAG CTT TCT TTG AAC CAA AAT TAG
T11F Rev GCA CCG AAG AAA CCC ATA CCA GCA GCT TTG CTT ACG TGA ATA CTA C
T11S T11S Rev GCA CCG AAG AAA CCC ATA CCA GCA GCA CCA CTA CAA TGA CAA GTT GC
T6m1 T6m1 Fwd AAC GGT GTT CAA CCA AAA TAC AAG TAA GCT TTC TTT GAA CC
T6S Rev ATT TTG GTT GAA CAC CGT TAC CAC TAC AAT GAC AAG TTG
T6m2 T6m1 Fwd AAC GGT GTT CAA CCA AAA TAC AAG TAA GCT TTC TTT GAA CC
T6m2 Rev GTA TTT TGG TTG AAC ACC GTT TAC ACT ACA ATG ACA AGT TGC TG
T6m3 T6F Fwd GGT GTT CAA CCA AAA TAC TAA GCT TTC TTT GAA CC
T6m2 Rev GTA TTT TGG TTG AAC ACC GTT TAC ACT ACA ATG ACA AGT TGC TG
T6m4 T6m4 Fwd CGG TGT TCA ACC AAA ATA CAC AGC AAC TTG TCA TTG TAG
T6m4 Rev GTA TTT TGG TTG AAC ACC GTT ACA ACC CAT CAG AGC TCC TG
T8m1 T8m1 Fwd CGC TAA GGT TGC TCT TAA AGC TCT TAA GTA AGC TTT CTT TGA AC
T8m1 Rev GAG CTT TAA GAG CAA CCT TAG CGA TTT TAC CAC TAC AAT GAC AAG TTG
T8m2 T8m1 Fwd CGC TAA GGT TGC TCT TAA AGC TCT TAA GTA AGC TTT CTT TGA AC
T8m2 Rev GAG CTT TAA GAG CAA CCT TAG CGA TTT TTA CAC TAC AAT GAC AAG TTG CTG TTT TC
T8m3 T8m3 Fwd CGC TAA GGT TGC TCT TAA AGC TCT TTA AGC TTT CTT TGA ACC
T8m2 Rev GAG CTT TAA GAG CAA CCT TAG CGA TTT TTA CAC TAC AAT GAC AAG TTG CTG TTT TC
T8m4 T8m4 Fwd CGC TAA GGT TGC TCT TAA AGC TCT TAC AGC AAC TTG TCA TTG TAG TAT TCA CG
T8m4 Rev GCT TTA AGA GCA ACC TTA GCG ATT TTA CAA CCC ATC AGA GCT CC
T16m1 T16m1 Fwd CCA CGT CCT CCA CAT CCA AGA TTG AAG TAA GCT TTC TTT GAA CCA AAA TTA G
T16m1 Rev CTT CAA TCT TGG ATG TGG AGG ACG TGG ACC ACT ACA ATG ACA AGT TGC TGT TTT C
T16m2 T16m1 Fwd CCA CGT CCT CCA CAT CCA AGA TTG AAG TAA GCT TTC TTT GAA CCA AAA TTA G
T16m2 Rev CAA TCT TGG ATG TGG AGG ACG TGG TAC ACT ACA ATG ACA AGT TGC TGT TTT C
T16m3 T16m3 Fwd CCA CGT CCT CCA CAT CCA AGA TTG TAA GCT TTC TTT GAA CC
T16m2 Rev CAA TCT TGG ATG TGG AGG ACG TGG TAC ACT ACA ATG ACA AGT TGC TGT TTT C
T16m4 T16m4 Fwd CACGTCCTCCACATCCAAGATTGACAGCAACTTGTCATTGTAGTATTC
T16m4 Rev CAA TCT TGG ATG TGG AGG ACG TGG ACA ACC CAT CAG AGC TCC
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